Rheumatoid Arthritis

Tofacitinib shows promising results in adult patients with moderately to severely active rheumatoid arthritis as a monotherapy with or without methotrexate.

Research investigates whether statins are safe and effective for patients with inflammatory conditions, such as rheumatoid arthritis.

A 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR, Pfizer) used in patients with rheumatoid arthritis increased the risk of blood clots in the lungs and death in a safety clinical trial.

The higher dose is only approved for patients with ulcerative colitis, and not for RA.

The New Drug Application for upadacitinib is supported by data from the phase 3 SELECT trial program evaluating patients with moderate-to-severe rheumatoid arthritis.

Rituximab is approved by the FDA for the treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.

The single-dose, prefilled autoinjector for tocilizumab (Actemra) offers an additional option for patients with rheumatoid arthritis, giant cell arteritis, and 2 forms of juvenile arthritis.

New data presented at the 2018 ACR/ARHP Annual Meeting shows that the treatment regimens for many patients are not being changed to reach a “treat-to-target” goal for low disease activity.

Adalimumab-adaz (Hyrimoz), a biosimilar of Humira, is the third FDA-approved Sandoz biosimilar in the United States.

Study evaluates when and how the increased risk of autoimmune thyroid disease develops in patients diagnosed with rheumatoid arthritis.

Patients with rheumatoid arthritis who achieve low disease activity or remission may successfully taper their biologic disease-modifying antirheumatic drugs, saving costs as a result.

Shifting Medicare Part B drugs into Part D may lead to higher costs for Medicare patients with rheumatoid arthritis, according to a new analysis.

By mapping out the epigenomic landscape of rheumatoid arthritis, scientists hope to gain insight on disease origins as well as new cell signaling pathways.

New report assesses the quality of rheumatic disease care across all 50 states and calls for improvements that address access to affordable care.

Top news of the week from Specialty Pharmacy Times.

New drug could serve as a potential treatment option for patients who have shown an inadequate response to conventional disease-modifying drugs.

The rate of disease progression in patients with rheumatoid arthritis (RA) can be associated with a poor prognosis in patients.

Childhood exposure to secondhand smoke may heighten the risk of developing rheumatoid arthritis (RA) later in life, even in non-smokers, according to new research.

Exposure to secondhand smoke in childhood can lead to greater risk of rheumatoid arthritis later in life, even in non-smoking adults.

A symposium presented at the Asembia Specialty Pharmacy Summit 2018 provided pharmacists a review of guideline-based RA management strategies, along with recent trial data on new and emerging agents.

In response to the Trump Administration’s drug pricing blueprint, the American College of Rheumatology issued a set of policy principles on drug prices and access to rheumatology treatment.

Upadacitinib is currently being tested in phase 3 trials of rheumatoid arthritis, psoriatic arthritis and Crohn’s disease, and is being investigated to treat ulcerative colitis, ankylosing spondylitis, atopic dermatitis and giant cell arteritis.

Baricitinib is indicated as a monotherapy or in combination with methotrexate or other disease-modifying antirheumatic drugs for adults with moderately-to-severely active rheumatoid arthritis.

The FDA has approved baricitinib (Olumiant), a once-daily oral drug for adults with moderately-to-severely active rheumatoid arthritis.

The 2019 Benefit and Payment Parameters final rule allows states to select their own Essential Health Benefits benchmark plans.

Top news of the day from across the health care landscape.

Upadacitinib, an oral agent designed to selectively inhibit JAK1, is being studied as a once-daily therapy in rheumatoid arthritis.

Upadacitinib met primary endpoints of ACR20 and clinical remission versus placebo in treatment of moderate to severe rheumatoid arthritis.

Genetic sequencing of joint biopsies may identify which patients with rheumatoid arthritis may respond to therapy.

With the introduction of biologics such as Humira, Enbrel, and Remicade to treat RA, prescription costs have steadily increased.